Results overview: Found 16 records in 0.02 seconds.
Articles, 16 records found
Articles 16 records found  1 - 10next  jump to record:
1.
10 p, 384.2 KB Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy / Ilson, David H. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Prokharau, Aliaksandr (Minsk City Clinical Oncology Dispensary) ; Arkenau, Hendrik-Tobias (University College London) ; Ghidini, Michele (Azienda Ospedaliera di Cremona) ; Fujitani, Kazumasa (Osaka General Medical Center) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Mansoor, Wasat (The Christie NHS Foundation Trust (Regne Unit)) ; Zhavrid, Edvard (Alexandrov National Cancer Centre of Belarus) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; George, Ben (Medical College of Wisconsin) ; Catenacci, Daniel (University of Chicago) ; McGuigan, Sandra (Taiho Oncology Inc) ; Makris, Lukas (Stathmi Inc) ; Doi, Toshihiko (National Cancer Center Hospital East (Japó)) ; Shitara, Kohei (National Cancer Center Hospital East (Japó)) ; Universitat Autònoma de Barcelona
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy. [...]
2019 - 10.1001/jamaoncol.2019.3531
JAMA Oncology, Vol. 6 (october 2019)  
2.
5 p, 637.4 KB Educational needs in gastrointestinal cancer : a consensus position paper from the ESMO Gastrointestinal Cancer Faculty / Lordick, Florian (Leipzig University Medical Center) ; Obermannova, Radka (Masaryk University) ; Vola, Doris (European Society for Medical Oncology) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Mcgregor, Keith (European Society for Medical Oncology) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ciardiello, Fortunato (Second University of Naples) ; Cervantes, Andrés (Universitat de València)
Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. [...]
2019 - 10.1136/esmoopen-2019-000533
ESMO open, Vol. 4 (july 2019)  
3.
11 p, 726.2 KB Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 / Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ; Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ; Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ; Muro, Kei (Aichi Cancer Center Hospital) ; Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ; Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ; Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ; Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ; Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ; Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ; Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ; Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ; Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 - 10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340  
4.
11 p, 588.4 KB Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma : results from the randomised phase III KEYNOTE-062 study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Valderrama, A. (Center for Observational and Real-World Evidence, Merck) ; Bang, Yung-Jue (Seoul National University College of Medicine) ; Fuchs, C. S. (Yale University Cancer Center) ; Shitara, Kohei (National Cancer Center Hospital East, Kashiwa, Japan) ; Janjigian, Y. Y. (Memorial Sloan Kettering Cancer Center) ; Qin, S. (PLA Cancer Centre of Nanjing Bayi Hospital) ; Larson, T. G. (Minnesota Oncology Hematology) ; Shankaran, V. (Seattle Cancer Care Alliance) ; Stein, S. (Yale University Cancer Center) ; Norquist, J. M. (Center for Observational and Real-World Evidence, Merck) ; Kher, U. (Department of Medical Oncology, Merck) ; Shah, S. (Department of Medical Oncology, Merck) ; Alsina, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (GEJ) cancer. [...]
2021 - 10.1016/j.esmoop.2021.100189
ESMO open, Vol. 6 (august 2021)  
5.
8 p, 1.6 MB Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer : a subgroup analysis from the phase 3 TAGS study / Mansoor, Wasat (The Christie NHS Foundation Trust) ; Arkenau, Hendrik-Tobias (University College London) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Shitara, Kohei (National Cancer Center Hospital East) ; Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ; Cuffe, Sinead (St. James's Hospital ( Dublín, Irlanda)) ; Dvorkin, Mikhail (Omsk Regional Clinical Centre of Oncology) ; Park, David (St, Joseph Heritage Healthcare) ; Ando, Takayuki (University of Toyama) ; Van Den Eynde, Marc (UCL Cliniques Universitaires Saint-Luc) ; Beretta, Giordano D. (Humanitas Gavazzeni) ; Zaniboni, Alberto (Fondazione Poliambulanza-Istituto Ospedaliero) ; Doi, Toshihiko (National Cancer Center Hospital East) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Ilson, David H. (Memorial Sloan Kettering Cancer Center) ; Makris, Lukas (Stathmi, Inc, New Hope, PA USA) ; Benhadji, Karim A. (Taiho Oncology) ; Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Universitat Autònoma de Barcelona
Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. [...]
2021 - 10.1007/s10120-021-01156-x
Gastric Cancer, Vol. 24 (march 2021) , p. 970-977  
6.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
7.
19 p, 418.6 KB Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study / Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Huijberts, Sanne (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ; Grothey, Axel (West Cancer Center, Germantown, TN) ; Yaeger, Rona (Memorial Sloan Kettering Cancer Center) ; Cuyle, Pieter-Jan (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Fakih, Marwan (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Wasan, Harpreet (Hammersmith Hospital (Londres)) ; Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ; Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli" (Nàpols, Itàlia)) ; Gollerkeri, Ashwin (Array BioPharma Inc) ; Christy-Bittel, Janna (Array BioPharma Inc) ; Maharry, Kati (Array BioPharma Inc) ; Sandor, Victor (Array BioPharma Inc) ; Schellens, Jan H. M. (Utrecht University) ; Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut de Recerca (VHIR)
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469  
8.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D. C. (The West Clinic, Memphis, USA) ; Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G. (St László Hospital (Hongria)) ; Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K. (Aichi Cancer Center Hospital) ; Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A. (Mayo Clinic, Phoenix, USA) ; O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ; Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
9.
9 p, 325.6 KB Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study / Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ; Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ; Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ; Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ; Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ; Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ; Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ; Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ; Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ; Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Taniguchi, H. (Aichi Cancer Center Hospital) ; Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ; Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ; Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ; Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ; Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ; Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963  
10.
16 p, 1.5 MB Health-related Quality of Life in the Phase III LUME-Colon 1 Study : Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses / Lenz, Heinz Joseph (Division of Medical Oncology. USC Norris Comprehensive Cancer Center) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Yoshino, Takayuki (Department of Gastroenterology and Gastrointestinal Oncology. National Cancer Center Hospital East) ; Lonardi, Sara (Phase 1 Trial Unit and Medical Oncology Unit 1. Istituto Oncologico Veneto IRCCS) ; Falcone, Alfredo (Department of Oncology. University of Pisa) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Sobrero, Alberto (Ospedale Policlinico San Martino IRCCS) ; Hastedt, Claudia (Boehringer Ingelheim International GmbH) ; Peil, Barbara (Boehringer Ingelheim Pharma GmbH & Co. KG) ; Voss, Florian (Boehringer Ingelheim Pharma GmbH & Co. KG) ; Griebsch, Ingolf (Boehringer Ingelheim International GmbH) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Universitat Autònoma de Barcelona
Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. [...]
2019 - 10.1016/j.clcc.2019.08.005
Clinical Colorectal Cancer, Vol. 18 Núm. 4 (december 2019) , p. 269-279.e5  

Articles : 16 records found   1 - 10next  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.